At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough (EPiCC)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Sep 13, 2011·Updated Nov 24, 2020
In Brief
A Phase 2 clinical trial evaluating Gefapixant and Placebo for Chronic Cough. Completed, enrolled 24 participants.
Detailed Summary
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to evaluate the effectiveness of gefapixant in reducing daytime objective cough frequency.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Cough
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartSep 2011
Primary CompletionFeb 2013
Study CompletionFeb 2013
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartSep 22, 2011
Primary CompletionFeb 7, 2013
Study CompletionFeb 21, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.8 years ago
Interventions
Gefapixantdrug
Oral tablets, BID
Placebodrug
Oral tablets, BID